Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1960 1
1961 3
1962 2
1963 7
1964 7
1965 9
1966 12
1967 16
1968 10
1969 10
1970 12
1971 10
1972 11
1973 12
1974 23
1975 17
1976 14
1977 21
1978 18
1979 21
1980 23
1981 29
1982 26
1983 26
1984 35
1985 37
1986 48
1987 38
1988 39
1989 49
1990 62
1991 58
1992 71
1993 81
1994 73
1995 77
1996 83
1997 94
1998 107
1999 111
2000 133
2001 121
2002 130
2003 133
2004 126
2005 147
2006 149
2007 149
2008 156
2009 164
2010 173
2011 214
2012 202
2013 197
2014 226
2015 203
2016 224
2017 246
2018 266
2019 318
2020 337
2021 332
2022 309
2023 149

Text availability

Article attribute

Article type

Publication date

Search Results

5,700 results

Results by year

Filters applied: . Clear all
Page 1
Endovascular Therapy for Acute Stroke with a Large Ischemic Region.
Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, Matsumaru Y, Matsumoto Y, Kimura K, Takeuchi M, Yazawa Y, Kimura N, Shigeta K, Imamura H, Suzuki I, Enomoto Y, Tokunaga S, Morita K, Sakakibara F, Kinjo N, Saito T, Ishikura R, Inoue M, Morimoto T. Yoshimura S, et al. Among authors: matsumoto y. N Engl J Med. 2022 Apr 7;386(14):1303-1313. doi: 10.1056/NEJMoa2118191. Epub 2022 Feb 9. N Engl J Med. 2022. PMID: 35138767 Clinical Trial.
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease.
Ban T, Kikuchi M, Sato GR, Manabe A, Tagata N, Harita K, Nishiyama A, Nishimura K, Yoshimi R, Kirino Y, Yanai H, Matsumoto Y, Suzuki S, Hihara H, Ito M, Tsukahara K, Yoshimatsu K, Yamamoto T, Taniguchi T, Nakajima H, Ito S, Tamura T. Ban T, et al. Among authors: matsumoto y. Nat Commun. 2021 Jul 19;12(1):4379. doi: 10.1038/s41467-021-24609-4. Nat Commun. 2021. PMID: 34282144 Free PMC article.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI, Yoshida T, Yagishita S, Ohuchi M, Sakiyama N, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Hamada A, Ohe Y. Higashiyama RI, et al. Among authors: matsumoto y. J Thorac Oncol. 2022 Oct;17(10):1227-1232. doi: 10.1016/j.jtho.2022.06.010. Epub 2022 Jul 3. J Thorac Oncol. 2022. PMID: 35788404
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese.
Tomofuji Y, Maeda Y, Oguro-Igashira E, Kishikawa T, Yamamoto K, Sonehara K, Motooka D, Matsumoto Y, Matsuoka H, Yoshimura M, Yagita M, Nii T, Ohshima S, Nakamura S, Inohara H, Takeda K, Kumanogoh A, Okada Y. Tomofuji Y, et al. Among authors: matsumoto y. Ann Rheum Dis. 2021 Dec;80(12):1575-1583. doi: 10.1136/annrheumdis-2021-220687. Epub 2021 Aug 23. Ann Rheum Dis. 2021. PMID: 34426398 Free PMC article.
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Shinno Y, et al. Among authors: matsumoto y. Clin Lung Cancer. 2022 Jul;23(5):386-392. doi: 10.1016/j.cllc.2022.03.005. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618627
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: matsumoto y. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685 Free article.
Randomized trial of granulocyte colony-stimulating factor for spinal cord injury.
Koda M, Hanaoka H, Fujii Y, Hanawa M, Kawasaki Y, Ozawa Y, Fujiwara T, Furuya T, Ijima Y, Saito J, Kitamura M, Miyamoto T, Ohtori S, Matsumoto Y, Abe T, Takahashi H, Watanabe K, Hirano T, Ohashi M, Shoji H, Mizouchi T, Kawahara N, Kawaguchi M, Orita Y, Sasamoto T, Yoshioka M, Fujii M, Yonezawa K, Soma D, Taneichi H, Takeuchi D, Inami S, Moridaira H, Ueda H, Asano F, Shibao Y, Aita I, Takeuchi Y, Mimura M, Shimbo J, Someya Y, Ikenoue S, Sameda H, Takase K, Ikeda Y, Nakajima F, Hashimoto M, Hasue F, Fujiyoshi T, Kamiya K, Watanabe M, Katoh H, Matsuyama Y, Hasegawa T, Yoshida G, Arima H, Yamato Y, Oe S, Togawa D, Kobayashi S, Akeda K, Kawamoto E, Imai H, Sakakibara T, Sudo A, Ito Y, Kikuchi T, Takigawa T, Morita T, Tanaka N, Nakanishi K, Kamei N, Kotaka S, Baba H, Okudaira T, Konishi H, Yamaguchi T, Ito K, Katayama Y, Matsumoto T, Matsumoto T, Kanno H, Aizawa T, Hashimoto K, Eto T, Sugaya T, Matsuda M, Fushimi K, Nozawa S, Iwai C, Taguchi T, Kanchiku T, Suzuki H, Nishida N, Funaba M, Sakai T, Imajo Y, Yamazaki M. Koda M, et al. Among authors: matsumoto y. Brain. 2021 Apr 12;144(3):789-799. doi: 10.1093/brain/awaa466. Brain. 2021. PMID: 33764445 Free PMC article. Clinical Trial.
Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion: A Secondary Analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT).
Uchida K, Shindo S, Yoshimura S, Toyoda K, Sakai N, Yamagami H, Matsumaru Y, Matsumoto Y, Kimura K, Ishikura R, Yoshida A, Inoue M, Beppu M, Sakakibara F, Shirakawa M, Morimoto T; RESCUE-Japan LIMIT Investigators. Uchida K, et al. Among authors: matsumoto y. JAMA Neurol. 2022 Dec 1;79(12):1260-1266. doi: 10.1001/jamaneurol.2022.3285. JAMA Neurol. 2022. PMID: 36215044 Clinical Trial.
Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.
Shirasaki T, Yamagoe S, Shimakami T, Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M. Shirasaki T, et al. Among authors: matsumoto y. Nat Commun. 2022 Jun 8;13(1):3176. doi: 10.1038/s41467-022-30879-3. Nat Commun. 2022. PMID: 35676290 Free PMC article.
5,700 results